Form 8-K NeuBase Therapeutics, For: Oct 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
RBC Capital Downgrades NeuBase Therapeutics (NBSE) to Sector Perform
October 18, 2022 5:23 AM EDTRBC Capital analyst Brian Abrahams downgraded NeuBase Therapeutics (NASDAQ: NBSE) from Outperform to Sector Perform with a price target of $1.00 (from $12.00).
The analyst comments "On Friday, NBSE announced a major restructuring as part of a cost-saving measure and we... More
